1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Crescita Therapeutics Inc.

Crescita Therapeutics Inc.

CTX.TO
Crescita Therapeutics Inc.CA flagToronto Stock Exchange
0.79
CAD
- -
- -
14.71MMarket Cap
Crescita Therapeutics Inc.
CTX.TO
(Toronto Stock Exchange)

Recent

price

0.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.08
0.02
0.27
0.86
0.84
1.07
0.76
0.81
1.14
0.87
1.01
1.12
1.24
Revenue per Share
-1.39
-1.35
-1.32
-0.82
0.12
0.09
- -
-0.05
0.04
-0.1
-0.14
- -
-0.02
Basic EPS, GAAP
-0.89
-1.22
-1.46
-0.54
-0.08
0.24
0.27
-0.09
-0.06
0.1
0.08
0.04
0.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-2.58
0.8
0.87
0.86
0.86
0.8
0.76
0.58
0.38
0.32
0.26
Book Value per Share
-0.2
-0.29
0.71
0.24
0.52
0.65
0.8
0.81
0.88
0.83
0.73
0.75
0.7
Tangible Book Value per Share
10
11
13
14
20
21
21
21
21
20
19
19
19
Basic Weighted Avg Shares
1
- -
4
12
17
22
16
17
24
18
20
21
23
Sales/Revenue/Turnover
-1,623.86
-3,243.86
-419.63
-51.72
-0.22
22.24
9.94
-4.29
2.25
-11.16
-16.42
-4.84
-5.02
Operating Margin (%)
- -
- -
- -
1
1
2
1
1
1
2
1
2
2
Depreciation Expense
-15
-15
-17
-11
2
2
- -
-1
1
-2
-3
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
41.67
92.88
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,759.16
-6,775.44
-481.85
-95.41
14.41
8.3
0.24
-6.59
3.66
-11.33
-14.04
-0.44
-1.38
Profit Margin (%)
-2
-3
17
6
11
12
15
13
14
14
10
11
10
Working Capital
- -
- -
7
3
3
1
1
2
1
1
- -
- -
2
LT Debt
-2
-3
24
13
19
21
21
21
21
19
16
16
14
Total Equity
- -
- -
- -
- -
- -
12.61
0.49
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
10.97
0.28
- -
- -
- -
- -
- -
-7.58
Return on Capital (%)
- -
- -
- -
- -
16.97
10.57
0.21
-6.42
5.34
-14.48
-28.81
-1.37
-5.77
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
9
9
14

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
16
16
16
Cash, Cash Equivalents & STI
8
9
9
Accounts Receivable, Net
2
2
2
Inventories
5
5
4
Total Current Liabilities
5
5
6
Payables & Accruals
5
4
5
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-83.36%
-5.67%
-1.6%
Free Cash Flow
-100.8%
-99.8%
-51.95%
Net Income, GAAP
-391.74%
-730.61%
-96.65%
Sales/Revenue/Turnover
176.41%
8.32%
7.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
4
4
7
20
2025
4
6
5
6
21
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.05
-0.05
- -
-0.14
2025
-0.05
0.04
0.04
- -
- -
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hemp Naturals, Inc. (HPMM)
HempAmericana, Inc (HMPQ)
Instadose Pharma Corp. (INSD)
Indiva Limited (NDVAF)
Ascend Wellness Holdings, Inc. (AAWH)
LFTD Partners Inc. (LIFD)
Business
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development and manufacturing capabilities that develops, manufactures and markets prescription and non-prescription skincare products for the treatment and care of skin conditions, diseases and associated symptoms; its core offerings span three segments including Commercial Skincare with branded non-prescription dermocosmetic products such as face creams, cleansers, exfoliants, masks, serums and suncare under brands like Laboratoire Dr Renaud, Aquafolia, Pro-Derm and Alyria to address mild acne, aging, dehydration, pigmentation, sensitivity and rosacea as well as medical aesthetics products including Pliaglis, a topical anesthetic cream, NCTF Boost 135 HA, ART FILLER and Obagi Medical in Canada, Licensing and Royalties encompassing intellectual property related to Pliaglis and transdermal delivery technologies, and Manufacturing and Services providing contract development, topical product manufacturing to client specifications and product development services. The company, founded in 2016 and headquartered in Laval, Quebec, Canada, primarily serves Canadian and international markets with approximately 80 employees and operates facilities including locations in Mississauga, Ontario. Recent developments include the June 2024 acquisition of non-real estate business assets from Occy Laboratory Inc. for CAD 657,000 to expand capabilities, the July 2024 signing of a five-year exclusive manufacturing and supply agreement with a leading Canadian healthcare services provider for sanitary products like hand sanitizer and lotion targeting publicly funded organizations with potential annual revenues up to CAD 6.0 million, the 2024 purchase of the Aquafolia brand which contributed to profitability, new partnerships in manufacturing and medical aesthetics, a new U.S. distribution agreement for Pliaglis, the May 2025 mutual termination of a prior Croma partnership that returned Pliaglis rights to Crescita alongside a EUR 575,000 payment and share repurchases under a normal course issuer bid during the first half of 2025.